Picture of Fresenius Medical Care AG logo

FME — Fresenius Medical Care AG News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

Germany's Fresenius Medical Q2 revenue beats; 2026 outlook reaffirmed

Germany's Fresenius Medical Q2 revenue beats; 2026 outlook reaffirmed


Overview

  • Germany dialysis provider's Q2 revenue rose 1% yr/yr, beating analyst expectations

  • Q2 operating income grew 10% yr/yr; net income declined 3%

  • Company reaffirmed 2026 outlook


Outlook

  • Fresenius Medical reaffirms 2026 revenue growth to be broadly flat versus prior year

  • Company expects 2026 operating income to be in a positive to negative mid-single digit percent range

  • 2026 outlook is at constant currency and excludes special items in operating income


Result Drivers

  • RATE AND REIMBURSEMENT EFFECTS - Co said positive rate effects and favorable TDAPA reimbursement regulations supported operating income growth

  • COST SAVINGS - FME25+ transformation program delivered EUR 67 mln in additional sustainable savings in Q2

  • 5008X CARESYSTEM ROLLOUT - Increased sales and rollout of 5008X CAREsystem in U.S. clinics contributed to segment growth


Company press release: ID:nPn2s1t75a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

EUR 4.86 bln

EUR 4.79 bln (7 Analysts)

Q2 Net Income

EUR 218 mln

Q2 Basic EPS

EUR 0.81

Q2 EBIT

EUR 466 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 8 "hold" and 8 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for Fresenius Medical Care AG is €41.50, about 7.5% below its August 3 closing price of €44.86

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Aug 3 - Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook

  • Aug 3 - BioNTech says Sobi's Oelkers will replace Sahin as CEO

  • Aug 3 - Supernus Q2 revenue rises on prescription volume; to merge with Indivior Pharma


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Fresenius Medical Care AG

See all news